All In MedTech

Device Trial Radar · NCT06672588

Magnetic Seizure Therapy for Schizophrenia - Trial

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 22, 2025

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Lead sponsor
Centre for Addiction and Mental HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of British Columbia
First posted
Nov 4, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).

Conditions

  • Treatment Resistant Schizophrenia
  • Schizophrenia
  • Schizoaffective Disorder

Interventions

  • Magnetic Seizure Therapy (MST)Device

    MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation at 100% machine output. Seizure threshold will follow prior protocols used for frontal MST. Patients will receive care and be managed by anaesthesia as per standard ECT practice.

  • Electroconvulsive Therapy (ECT)Device

    In the ECT arm treatment, the MECTA sigma machine will be used. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold. Patients will receive care and be managed by anaesthesia as per standard ECT practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Brief Psychiatric Rating Scale (BPRS) Response (18-Version)Time frame: Greater than 8 treatments (2.5 weeks)
  2. MATRICS™ Consensus Cognitive Battery (MCCB)Time frame: Greater than 8 treatments (2.5 weeks)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of British Columbia Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • Centre for Addiction and Mental Health

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.